December 16, 2016 / 12:30 PM / 8 months ago

BRIEF-Ionis earns $28 mln from Astrazeneca for drug to treat cancer

Dec 16 (Reuters) - Ionis Pharmaceuticals Inc

* Ionis Pharmaceuticals - as ionis-kras-2.5(rx) advances in development, co eligible for up to $137 million additional development, milestone payment

* Ionis Pharmaceuticals inc - astrazeneca will be responsible for further developing and commercializing ionis-kras-2.5

* In addition, ionis is eligible to receive up to low double-digit royalties from sales of drug

* Ionis earns $28 million from astrazeneca for a new drug to treat cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below